{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:22Z","timestamp":1793971942595,"version":"4.8.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UKRI Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.canlet.2024.216871","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T22:17:43Z","timestamp":1712701063000},"page":"216871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors"],"prefix":"10.1016","volume":"591","author":[{"given":"Lihong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa Chard","family":"Dunmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiwen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216871_bib1","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.canlet.2024.216871_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.canlet.2024.216871_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214255","article-title":"Learning from TCR signaling and immunological synapse assembly to bulid new chimeric antigen receptors (CARs)","volume":"23","author":"Cassioli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216871_bib4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/glycob\/cwy008","article-title":"Glycan-directed CAR-T cells","volume":"28","author":"Steentoft","year":"2018","journal-title":"Glycobiology"},{"key":"10.1016\/j.canlet.2024.216871_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216871_bib7","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib8","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216871_bib9","article-title":"Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aap9777","article-title":"An immunoproteomic approach to characterize the CAR interactome and signalosome","volume":"12","author":"Ramello","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2024.216871_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan1088","article-title":"Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density","volume":"11","author":"James","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2024.216871_bib12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216871_bib13","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216871_bib14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216871_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836549","article-title":"Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4-1BB co-stimulation","volume":"13","author":"Halim","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957157","article-title":"Road testing new CAR design strategies in multiple myeloma","volume":"13","author":"Rana","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.canlet.2024.216871_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nbt.4090","article-title":"Driving T-cell immunotherapy to solid tumors","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2024.216871_bib20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216871_bib21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s11010-022-04435-y","article-title":"The miR-183\/96\/182 cluster is upregulated in glioblastoma carrying EGFR amplification","volume":"477","author":"Schneider","year":"2022","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.canlet.2024.216871_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, Infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib23","first-page":"575","article-title":"Key problems and countermeasures of the immunotherapy for solid tumors","volume":"24","author":"Liu","year":"2017","journal-title":"Chin J Cancer Biother"},{"key":"10.1016\/j.canlet.2024.216871_bib24","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.7150\/jca.25775","article-title":"The expression of FAP in hepatocellular carcinoma cells is induced by hypoxia and correlates with poor clinical outcomes","volume":"9","author":"Zou","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3892\/ijo.2016.3779","article-title":"Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells","volume":"50","author":"Shan","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yexmp.2018.11.014","article-title":"MiR-141-3p suppresses gastric cancer induced transition of normal fibroblast and BMSC to cancer-associated fibroblasts via targeting STAT4","volume":"107","author":"Zhou","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.canlet.2024.216871_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.09.016","article-title":"Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer","volume":"523","author":"Fan","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216871_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215946","article-title":"Lysophosphatidic acid-induced amphiregulin secretion by cancer-associated fibroblasts augments cancer cell invasion","volume":"551","author":"Jeong","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216871_bib29","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.3390\/ijms23169314","article-title":"CXCL14 attenuates triple-negative breast cancer progression by regulating immune profiles of the tumor microenvironment in a T cell-dependent manner","volume":"23","author":"Gibbs","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216871_bib30","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/cancers14153826","article-title":"Chemokine receptor expression on T cells Is modulated by CAFs and chemokines affect the spatial distribution of T cells in pancreatic tumors","volume":"14","author":"Gorchs","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216871_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216871_bib32","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.4049\/jimmunol.178.9.5552","article-title":"Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells","volume":"178","author":"Nazareth","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.canlet.2024.216871_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216871_bib36","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216871_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semradonc.2004.04.008","article-title":"Tumor microenvironmental physiology and its implications for radiation oncology","volume":"14","author":"Vaupel","year":"2004","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/ijc.25176","article-title":"Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination","volume":"127","author":"Rofstad","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3390\/cells9040992","article-title":"Hypoxia-driven immune escape in the tumor microenvironment","volume":"9","author":"Vito","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.216871_bib40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/jcp.2003.015032","article-title":"The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis","volume":"57","author":"Greijer","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.canlet.2024.216871_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.20892\/j.issn.2095-3941.2018.0304","article-title":"STIM1 overexpression in hypoxia microenvironment contributes to pancreatic carcinoma progression","volume":"16","author":"Wang","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.canlet.2024.216871_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gene.2019.04.029","article-title":"Gastrin promotes angiogenesis by activating HIF-1\u03b1\/\u03b2-catenin\/VEGF signaling in gastric cancer","volume":"704","author":"Tang","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.canlet.2024.216871_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40169-019-0226-9","article-title":"Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma","volume":"8","author":"Daniel","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216871_bib44","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1073\/pnas.0409910102","article-title":"Culturing at atmospheric oxygen levels impacts lymphocyte function","volume":"102","author":"Atkuri","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2024.216871_bib45","doi-asserted-by":"crossref","first-page":"E2784","DOI":"10.1073\/pnas.1202366109","article-title":"Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa","volume":"109","author":"Clambey","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2024.216871_bib46","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1111\/j.1365-2567.2008.02954.x","article-title":"Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin","volume":"128","author":"Yang","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2024.216871_bib47","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.4049\/jimmunol.167.11.6140","article-title":"Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions","volume":"167","author":"Caldwell","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrc.2017.110","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824643","article-title":"Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway","volume":"9","author":"Li","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216871_bib50","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2024.216871_bib51","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","article-title":"Tumor cell metabolism: cancer's Achilles' heel","volume":"13","author":"Kroemer","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gendis.2017.02.003","article-title":"Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment","volume":"4","author":"Jiang","year":"2017","journal-title":"Genes Dis"},{"key":"10.1016\/j.canlet.2024.216871_bib54","first-page":"1284","article-title":"Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism","volume":"8","author":"Helmlinger","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216871_bib55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10555-019-09792-7","article-title":"Causes, consequences, and therapy of tumors acidosis","volume":"38","author":"Pillai","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2024.216871_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4939-3023-4_27","article-title":"Acidosis promotes metastasis formation by enhancing tumor cell motility","volume":"876","author":"Riemann","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2024.216871_bib57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10585-008-9145-7","article-title":"Acid treatment of melanoma cells selects for invasive phenotypes","volume":"25","author":"Moellering","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2024.216871_bib58","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ygyno.2006.05.043","article-title":"Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF\/VEGFR2(KDR) pathway and prognosis","volume":"103","author":"Giatromanolaki","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib59","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","article-title":"Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes","volume":"72","author":"Calcinotto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216871_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/imm.12917","article-title":"Hypoxia and acidosis: immune suppressors and therapeutic targets","volume":"154","author":"Damgaci","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2024.216871_bib61","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","article-title":"Lactate: a metabolic key player in cancer","volume":"71","author":"Hirschhaeuser","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216871_bib62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib64","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2024.216871_bib65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-016-0200-7","article-title":"Canine cancer immunotherapy studies: linking mouse and human","volume":"4","author":"Park","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/CJI.0000000000000052","article-title":"Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells","volume":"37","author":"Mata","year":"2014","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2024.216871_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113118","article-title":"The role of neoantigens in tumor immunotherapy","volume":"151","author":"Shang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2024.216871_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1891814","article-title":"Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer","volume":"18","author":"Yu","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.canlet.2024.216871_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2080329","article-title":"MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy","volume":"11","author":"Baleeiro","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216871_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122062","article-title":"Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity","volume":"296","author":"Manna","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2024.216871_bib73","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","article-title":"Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues","volume":"3","author":"Feng","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib74","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1158\/1535-7163.MCT-21-0872","article-title":"Olfactory receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors","volume":"21","author":"Martin","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canlet.2024.216871_bib75","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216871_bib76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.canlet.2024.216871_bib77","article-title":"Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform","volume":"S1465\u20133249","author":"Trainor","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2024.216871_bib78","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcyt.2022.10.007","article-title":"Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells","volume":"25","author":"Halliwell","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2024.216871_bib79","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216871_bib80","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216871_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109559","article-title":"Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme","volume":"137","author":"Sabahi","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.canlet.2024.216871_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"499","key":"10.1016\/j.canlet.2024.216871_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.canlet.2024.216871_bib84","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib85","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib86","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216303","article-title":"A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma","volume":"568","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216871_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216871_bib90","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","article-title":"CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function","volume":"9","author":"Boucher","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.216871_bib91","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216871_bib92","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-022-01288-2","article-title":"C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction","volume":"15","author":"Lai","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib93","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3389\/fimmu.2019.01574","article-title":"The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib94","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2024.216871_bib95","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/mt.2015.199","article-title":"Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T cells to IL13R\u03b12-positive glioma","volume":"24","author":"Krenciute","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216871_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","volume":"12","author":"Bell","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib97","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216871_bib98","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.canlet.2024.216871_bib99","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4322092","article-title":"IL-21\/IL-21R regulates the neutrophil-mediated pathologic immune response during chlamydial respiratory infection","volume":"2022","author":"Zeng","year":"2022","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.canlet.2024.216871_bib100","first-page":"78","article-title":"Interleukin-21 and Interleukin-32 gene expression levels and their relationship with clinicopathological parameters in colorectal cancer","volume":"92","author":"Ozmen","year":"2022","journal-title":"Ann. Ital. Chir."},{"key":"10.1016\/j.canlet.2024.216871_bib101","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2011.40.0655","article-title":"Interleukin-21 has activity in patients with metastatic melanoma: a phase II study","volume":"30","author":"Petrella","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216871_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.675179","article-title":"IL-21 optimizes the CAR-T cell preparation through improving lentivirus mediated transfection efficiency of T cells and enhancing CAR-T cell cytotoxic activities","volume":"8","author":"Du","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2024.216871_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2024.216871_bib104","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216871_bib105","article-title":"Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216871_bib106","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2024.216871_bib107","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2024.216871_bib108","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216871_bib109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/ITT.S291767","article-title":"Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma","volume":"10","author":"Bughda","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.canlet.2024.216871_bib110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216871_bib111","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","article-title":"A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy","volume":"34","author":"Ye","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.canlet.2024.216871_bib112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","article-title":"Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells","volume":"39","author":"Masoumi","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216871_bib113","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41586-023-06546-y","article-title":"Reductive carboxylation epigenetically instructs T cell differentiation","volume":"621","author":"Jaccars","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216871_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.canlet.2024.216871_bib115","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-Based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216871_bib116","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216871_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216871_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.216871_bib119","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","article-title":"Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216871_bib120","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2024.216871_bib121","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216871_bib122","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2024.216871_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216871_bib124","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:11:44Z","timestamp":1784945504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524002647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":124,"alternative-id":["S0304383524002647"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216871","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216871"}}